Skip to Main Content
Contribute Try STAT+ Today

Cancer, one of the most complex diseases we face today, is a challenge to study and treat. The once carefully ordered world of cancer diagnosis and treatment — breast cancer is one thing, lung cancer is another — has been upended by genetic analyses showing that there are many types of each cancer, and these types evolve differently, making it difficult to predict the progression of the disease and choose the optimal treatment for it.

While research can help improve both diagnosis and treatment, the proportion of people with cancer who participate in clinical trials is notoriously low: Of the estimated 1.7 million new cases of cancer diagnosed in the U.S. each year, only about 5% of cancer patients are enrolled in clinical trials. Despite the numbers, cancer drug innovation is exploding — the FDA approved 19 new cancer drugs and biologics last year alone.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.